Open Access

Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review)

  • Authors:
    • Nitin Telang
  • View Affiliations

  • Published online on: December 5, 2018     https://doi.org/10.3892/wasj.2018.3
  • Pages: 20-24
  • Copyright: © Telang . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The global profiling of differentially expressed genes in subtypes of clinical breast cancer identifies predictive and prognostic biomarkers for disease progression and rationalizes breast cancer subtype‑based treatment options. The expression status of hormone and growth factor receptors dictates the options for chemo‑endocrine and/or pathway selective small molecule inhibitor‑based treatments. Overall, these treatment options are associated with long‑term systemic toxicity and acquired tumor resistance, predominantly due to the emergence of drug‑resistant cancer stem cell population and due to therapy‑resistant disease progression. These limitations emphasize the identification of non‑toxic testable therapeutic alternatives for the efficacious targeting of breast cancer stem cells. The present review summarizes published evidence focused on i) developing cellular models for molecular subtypes of breast cancer; ii) isolating and characterizing drug‑resistant cancer stem cells from the developed models; and iii) identifying mechanistic leads for potential stem cell‑targeting lead compounds. Cellular models for Luminal A, human epidermal growth factor receptor‑2 (HER‑2) enriched and triple‑negative breast cancer subtypes represented the experimental models. Prototypic chemo‑endocrine therapeutic agents were used to select the drug‑resistant stem cell phenotype. The vitamin A derivative, all‑trans retinoic acid, and the rosemary terpenoid, carnosol, respectively representing a mechanistically distinct natural product and a potential bio‑active constituent of a nutritional herb provided stem cell‑selective lead compounds. The cellular models for Luminal A, HER‑2‑enriched and triple‑negative breast cancer subtypes exhibited growth inhibitory effects in response to treatment with prototypic chemo‑endocrine therapeutics, natural products and nutritional herbs. Drug‑resistant phenotypes exhibited an upregulated expression of stem cell‑specific cellular and molecular markers. Lead compounds induced the downregulated expression of the stem cell markers in drug‑resistant phenotypes. These data validate an experimental approach with which to identify potential non‑toxic natural products and nutritional herbs that may represent testable alternatives for the stem cell targeted therapy of breast cancer.

1. Introduction

Metastatic breast cancer represents a major cause of mortality in women in the USA. A recent report from the American Cancer Society estimated 266,120 newly diagnosed cases of breast cancer and 41,400 breast cancer-related deaths in 2019(1). The global gene expression profiling of clinical breast cancers has provided a molecular classification based on hormone receptor and growth factor receptor expression (2). The identification of molecular subtypes dictates specific chemo-endocrine therapy and pathway selective small molecule inhibitor-based treatment options. Thus, selective estrogen receptor modulators, selective estrogen receptor degraders, aromatase inhibitors with or without CDK 4/6 inhibitors (3-5), human epidermal growth factor receptor-2 (HER-2)-targeted (6), PI3K/AKT-targeted or m-TOR-targeted (7-10) therapeutic options represent the treatment of choice. Long-term therapy is frequently associated with systemic toxicity and acquired tumor resistance due to the emergence of drug-resistant cancer stem cell populations that collectively compromise patient compliance and favor therapy-resistant cancer progression (11). These limitations emphasize the identification of non-toxic testable alternatives for the efficacious stem cell targeted treatment of breast cancer.

Naturally occurring phytochemicals and nutritional herbs are extensively used in alternative medicine and traditional Chinese medicine for general health issues, as well as for the palliative treatment for breast cancer. These agents have documented growth inhibitory efficacy via distinct mechanisms in cellular models of Luminal A, HER-2-enriched and triple-negative molecular subtypes of clinical breast cancer (12,13). These relatively non-toxic agents may provide testable alternatives for chemo-endocrine therapy-resistant breast cancer by targeting drug-resistant cancer stem cells.

The present review summarizes experimental data on optimizing cellular models for select breast cancer subtypes, isolating and characterizing drug-resistant stem cell phenotypes and providing mechanistic leads for potential lead compounds for the stem cell targeted therapy of clinical breast cancer.

2. Cellular models

Human breast carcinoma-derived cell lines provide valuable cellular models for molecular subtypes (14,15). Table I summarizes the status of hormone and growth factor receptor expression in cellular models for select breast cancer subtypes. The hormone receptor-positive, HER-2-negative Luminal A subtype responds to endocrine therapy comprising of selective estrogen receptor modulators, aromatase inhibitors and CDK 4/6 inhibitors. The hormone receptor-positive, HER-2-positive Luminal B subtype responds to endocrine therapy and to HER-2 targeted therapy. The hormone receptor-negative, HER-2-positive HER-2 enriched subtype responds to cytotoxic chemotherapy and HER-2 targeted therapy. The hormone receptor-negative HER-2-negative triple-negative subtype responds to cytotoxic chemotherapy and select small molecule inhibitors. Thus, the molecular classification has provided valuable leads for breast cancer subtype-selective therapeutic interventions (2-10).

Table I.

Cellular models for the molecular subtypes of clinical breast cancer.

Table I.

Cellular models for the molecular subtypes of clinical breast cancer.

ModelReceptor statusMolecular subtype
MCF-7ER+, PR+, HER-2-Luminal A
T47DER+, PR+, HER-2-Luminal A
BT474ER+, PR+, HER-2+Luminal B
MDA-MB-361ER+, PR+, HER-2+Luminal B
SKBr-3ER-, PR-, HER-2+HER-2-enriched
184-B5/HERER-, PR-, HER-2+HER-2-enriched
MDA-MB-231ER-, PR-, HER-2-Triple-negative

[i] ER, estrogen receptor-α; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2. [Data are summarized from previous studies (14,15,21)].

3. Test agents

Mechanistically distinct clinically relevant therapeutic agents, natural products and select nutritional herbs represented the test agents in the cellular models for Luminal A, HER-2-enriched and triple-negative molecular subtypes of clinical breast cancer. Table II summarizes the maximum cytostatic concentrations and clinical applications of the test agents. Tamoxifen (TAM), Lapatinib (LAP) and Doxorubicin (DOX) represented the positive controls for Luminal A, HER-2-enriched and triple-negative models, respectively (16,17). The maximum cytostatic concentrations of these agents, identified by dose response experiments were used to select the drug-resistant phenotype. The vitamin A derivative, all-trans retinoic acid (ATRA) and the rosemary terpenoid, carnosol (CSOL), were utilized to examine their efficacy on the cancer stem cell phenotype.

Table II.

Test agents.

Table II.

Test agents.

AgentIdentityMaximum cytostatic concentration (IC90)aClinical application
TAMSERM1.5 µMAnti-estrogen therapy
LAPEGFR/HER-2 inhibitor10 µMAnti-HER-2 therapy
DOXAnthracyclin0.5 µMChemotherapy
ATRAVitamin A derivative3 µMRetinoid therapy
CSOLRosemary terpenoid5 µMNutritional herb
CO 0.07-0.5%Nutritional herb
EG 0.44%Nutritional herb
DA 0.03%Nutritional herb

[i] aDetermined from day 7 post-seeding of 1.0x105 cells. TAM, Tamoxifen; LAP, Lapatinib; DOX, Doxorubicin; ATRA, all-trans retinoic acid; CSOL, carnosol; CO, Cornus officinalis; EG, Epimedium grandiflorum; DA, Dipsacus asperoides. [Data are summarized from previous studies (16,17,19-22)].

Mechanistic evidence for the growth inhibitory efficacy of relatively non-toxic natural products, including gucosinolates, polyphenols, isoflavones and terpenoids, as well as nutritional herbs suggest the potential applicability of these agents as testable alternatives for conventional chemo-endocrine therapy (12,18-21).

4. Mechanistic efficacy

Published evidence summarized in Table III has identified susceptible mechanistic pathways and potential molecular targets for the growth inhibitory efficacy of test agents in cellular models for breast cancer subtypes. Thus, in the Luminal A model represented by MCF-7 cells, TAM, Cornus officinalis (CO) and Epimedium grandiflorum (EG) inhibit anchorage-independent colony formation, induce G1 phase arrest and apoptosis (12,13,18). In the HER-2-enriched model represented by 184-B5/HER cells, ATRA and CSOL inhibit colony formation, induce G2/M phase arrest and inhibit cyclooxygenase (COX)-2 expression (21-23). In the triple-negative model represented by MDA-MB-231 cells, the anti-proliferative effects of CO and DA involve the RB and Ras signaling pathways, respectively (19,20). With regard to the nutritional herbs, it is conceivable that individual herbs may contain multiple bioactive agents. Thus, CO represents a major source for biologically active anthocyanins (24,25), EG contains Icariin and icaritin (26,27), and several Chinese nutritional herbs that contain flavonoids, including DA and EG may be effective in the prevention/therapy of metastatic breast cancer (28,29). These bio-active agents may in part be responsible for the growth inhibitory efficacy of the nutritional herbs.

Table III.

Mechanistic efficacy of test agents in breast cancer models.

Table III.

Mechanistic efficacy of test agents in breast cancer models.

ModelClinical subtypeAgentMolecular targets
MCF-7Luminal ATAM, CO, EGAIC, G1 arrest, apoptosis, BCL-2/BAX
184-B5/HERHER-2 enrichedATRA, CSOLAIC, RAR-β, COX-2, G2/M arrest, cyclin B1
MDA-MB-231TNBCCO DAG1-S transition, cyclin D1, RB RB, cyclin D1, CDK4/6, RAF/MEK/ERK, CDKI p21

[i] TAM, Tamoxifen; CO, Cornus officinalis; EG, Epimedium grandiflorum; ATRA, all-trans retinoic acid; CSOL, carnosol; DA, Dipsacus asperoides; AIC, anchorage-independent growth; BCL-2, B-cell lymphoma-2; BAX, BCL-2-associated X protein; RAR-β, retinoic acid receptor-β; COX-2, cyclooxygenase-2; RB, retinoblastoma; CDK, cyclin-dependent kinase; RAF/MEK/ERK, RAS-mediated down-stream signaling protein molecules; CDKI, cyclin-dependent kinase inhibitor. [Data are summarized from previous studies (18-23)].

5. Drug-resistant stem cell models

Drug-resistant stem cell phenotypes were selected from MCF-7, 184-B5/HER and MDA-MB-231 parental cells, based on their progressive growth in the presence of cytotoxic concentrations of TAM, LAP and DOX, respectively (30). Cellular markers, including tumor spheroid formation and the expression of CD44 have documented selectivity for cancer stem cells. In addition, nuclear transcription factors, including octamer-binding transcription factor-4 (Oct-4), Kruppel-like factor-4 (Klf-4), sex determining region Y-box-2 (SOX-2), c-Myc and NANOG exhibit stem cell selectivity, and these nuclear factors are also critical for the maintenance of induced pluripotent stem cells (31-33). The TAM-R, LAP-R and DOX-R phenotypes were characterized for their stem cell properties by examining the status of the expression of select stem cell-specific cellular and molecular markers. The stem cell-specific cellular markers included tumor spheroid formation and CD44 expression. The stem-cell specific molecular markers included the nuclear transcription factors, Oct-4 and NANOG. The primary data for the status of these cellular and molecular markers were obtained as incidence of tumor spheroids and as log mean immunofluorescence for the expression of CD44, Oct-4 and NANOG (30). These primary data were expressed as marker modulation (%). The data presented in Table IV are summarized as the extent of modulation in marker expression relative to the drug sensitive phenotype. These data clearly demonstrated that the three drug-resistant stem cell phenotypes exhibited a substantial increase in the expression of stem cell-specific cellular and molecular markers.

Table IV.

Drug-resistant stem cell models.

Table IV.

Drug-resistant stem cell models.

Resistant phenotypeDrug concentration (IC90)Stem cell marker expression (relative to sensitive phenotype)
  Tumor spheroidsCD44Oct-4NANOG
TAM-RTAM 1.5 µM+1.7X+3.8X+1.8X+1.9X
LAP-RLAP 10 µM+2.3X+4.2X+1.9X+4.4X
DOX-RDOX 0.5 µM+2.8X+4.4X+2.3X+1.5X

[i] Tumor spheroid: ISD: 100 cells; spheroid count: day 14 post-seeding. ISD, initial seeding density; TAM-R, Tamoxifen-resistant; LAP-R, Lapatinib-resistant; DOX-R, Doxorubicin-resistant; CD44, cluster of differentiation 44; Oct-4, octamer binding transcription factor-4; NANOG, homeobox transcription factor, X, fold. [Data are summarized from previous studies; for TAM-R and DOX-R (16,17,30); Data are summarized from unpublished results for LAP-R].

6. Stem cell-selective lead compound efficacy

The primary data from the experiment designed to examine the stem cell-targeted efficacy of natural products were obtained as the incidence of tumor spheroid and as log mean immuno-fluorescence (17,21,30). The data presented in Table V summarize the marker modulation (%) induced by the natural products, relative to the solvent treated control. These data demonstrate that in response to treatment with the vitamin A derivative, ATRA, and with the rosemary terpenoid, CSOL, the expression of select stem cell markers was substantially downregulated. In this context, it is noteworthy that these agents exhibit anti-proliferative and pro-apoptotic effects via distinct mechanisms on parental 184-B5/HER cells that represent a cellular model for the HER-2-enriched breast cancer subtype (21-23). Additionally, ATRA targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth (34).

Table V.

Effects of retinoid and terpenoids on LAP-R 184-B5/HER stem cells.

Table V.

Effects of retinoid and terpenoids on LAP-R 184-B5/HER stem cells.

TreatmentConcentration (IC90 µM)Stem cell marker expression (relative to solvent control)
  Tumor spheroidsCD44Oct-4NANOG
ATRA3 µM-69.1%-80.9%-81.9%-71.6%
CSOL5 µM-80.3%-84.4%-69.0%-74.3%

[i] ATRA, all-trans retinoic acid; CSOL, carnosol; CD44, cluster of differentiation 44; Oct-4, octamer binding transcription factor; NANOG, homeobox transcription factor. (Data are summarized from unpublished results).

7. Conclusions and future prospects

Human tissue-derived preclinical models provide valuable approaches to reduce the extrapolation for the potential clinical translation of the data. The present review summarized the application of cellular models for select molecular subtypes of clinical breast cancer that is targeted towards developing drug-resistant cancer stem cell models. Collectively, the present review has validated approaches that identify potential testable alternatives for the stem cell targeted therapy of breast cancer. Additionally, the present review provides a rational basis for future experiments on breast cancer explant models for lead compound screening (35), patient-derived tumor xenograft models for Luminal B and triple-negative breast cancer subtypes (36), and ex vivo breast cancer organoids from chemo-endocrine therapy-resistant breast cancer (37).

Acknowledgements

The author gratefully acknowledges the productive collaboration and active participation of former colleagues in the research program entitled ‘Cellular models for molecular subtypes of clinical breast cancer: Mechanistic approaches for lead compound efficacy’.

Funding

This research program has been funded in the past by US National Cancer Institute (NCI) FIRST Award (grant no. CA 44741), Program Project Grant (grant no. PO1 CA 29502), NCI Contract Research Master Agreement (grant no. CN 75029-63), the Department of Defense Breast Cancer Research Program IDEA Award (grant no. DAMD-17-94-J-4208), and by the philanthropic funds to Strang Cancer Prevention Center.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Author's contributions

The author contributed towards study conception, experimental design and data interpretation, and prepared the manuscript for publication.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The author declares that there are no competing interests.

References

1 

American Cancer Society-Facts and Figures: American Cancer Society Atlanta. GA. 2018.

2 

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar

3 

Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009.PubMed/NCBI View Article : Google Scholar

4 

Johnston SR and Dowsett M: Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer. 3:821–831. 2003.PubMed/NCBI View Article : Google Scholar

5 

Ma CX, Reinert T, Chmielewska I and Ellis MJ: Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 15:261–275. 2015.PubMed/NCBI View Article : Google Scholar

6 

Baselga J and Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009.PubMed/NCBI View Article : Google Scholar

7 

Dinh P, Sotiriou C and Piccart MJ: The evolution of treatment strategies: Aiming at the target. Breast. 16((Suppl 2)): S10–S16. 2007.PubMed/NCBI View Article : Google Scholar

8 

Cleator S, Heller W and Coombes RC: Triple-negative breast cancer: Therapeutic options. Lancet Oncol. 8:235–244. 2007.PubMed/NCBI View Article : Google Scholar

9 

Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW and Carey LA: Poly(ADP-Ribose) polymerase inhibition: ‘Targeted’ therapy for triple-negative breast cancer. Clin Cancer Res. 16:4702–4710. 2010.PubMed/NCBI View Article : Google Scholar

10 

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2:1036–1047. 2012.PubMed/NCBI View Article : Google Scholar

11 

Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.PubMed/NCBI View Article : Google Scholar

12 

Telang N and Katdare M: Epithelial cell culture models for the prevention and therapy of clinical breast cancer (Review). Oncol Lett. 3:744–750. 2012.PubMed/NCBI View Article : Google Scholar

13 

Telang N, Li G, Katdare M, Sepkovic D, Bradlow L and Wong G: Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function. Oncol Lett. 12:3949–3957. 2016.PubMed/NCBI View Article : Google Scholar

14 

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cell. 10:515–527. 2006.PubMed/NCBI View Article : Google Scholar

15 

Subik K, Lee JF, Baxter L, Strzepel T, Costello D, Crowley P, Xing L, Hung MC and Bonfiglio T: Hicks DG and tangP; Expression patterns of ER, PR, HER-2, CK5/6, Ki-67 and AR by immune-histochemical analysis in breast cancer cell lines. Breast Cancer. 4:35–41. 2010.PubMed/NCBI

16 

Telang N: Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI View Article : Google Scholar

17 

Telang N: Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer. Biomed Rep. 7:199–204. 2017.PubMed/NCBI View Article : Google Scholar

18 

Telang NT, Li G, Sepkovic DW, Bradlow HL and Wong GY: Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI View Article : Google Scholar

19 

Telang NT, Nair HB and Wong GY: Effect of Cornus officinalis (CO) on a model for triple negative breast cancer. Cancer Res. 75((Suppl): SABCS Abstract P3-09-04)2015. View Article : Google Scholar

20 

Telang N, Nair HB and Wong GY: Efficacy of Disacus asperoides (DA) in a model for triple negative breast cancer. Cancer Res. 76((Suppl): SABCS Abstract P4-13-04)2016. View Article : Google Scholar

21 

Telang N: Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar

22 

Jinno H, Steiner MG, Nason-Burchenal K, Osborne MP and Telang NT: Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells. Int J Oncol. 21:127–134. 2002.PubMed/NCBI View Article : Google Scholar

23 

Subbaramaiah K, Cole PA and Dannenberg AJ: Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 62:2522–2530. 2002.PubMed/NCBI

24 

Seeram NP, Schutzki R, Chandra A and Nair MG: Characterization, quantification, and bioactivities of anthocyanins in Cornus species. J Agric Food Chem. 50:2519–2523. 2002.PubMed/NCBI View Article : Google Scholar

25 

Chang JS, Chiang LC, Hsu FF and Lin CC: Chemoprevention against hepatocellular carcinoma of Cornus officinalis in vitro. Am J Chin Med. 32:717–725. 2004.PubMed/NCBI View Article : Google Scholar

26 

Sun L, Chen W, Qu L, Wu J and Si J: Icaritin reverses multidrug resistance of HepG2/ADR human hepatoma cells via downregulation of MDR1 and P glycoprotein expression. Mol Med Rep. 8:1883–1887. 2013.PubMed/NCBI View Article : Google Scholar

27 

Ma HR, Wang J, Chen YF, Chen H, Wang WS and Aisa HA: Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway. Int J Mol Med. 33:1627–1634. 2014.PubMed/NCBI View Article : Google Scholar

28 

Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar

29 

Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL and Wong GY: The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer. Oncol Lett. 13:2477–2482. 2017.PubMed/NCBI View Article : Google Scholar

30 

Telang NT: Drug resistant breast colon cancer stem cells: Targeted approach for stem cell therapy. Int J Mol Med. 42((Suppl 1): S6)2018.PubMed/NCBI View Article : Google Scholar

31 

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131:861–872. 2007.PubMed/NCBI View Article : Google Scholar

32 

Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 451:141–146. 2008.PubMed/NCBI View Article : Google Scholar

33 

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II and Thomson JA: Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324:797–801. 2009.PubMed/NCBI View Article : Google Scholar

34 

Nguyen PH, Giraud J, Staedel C, Chambonnier L, Dubus P, Chevret E, Bœuf H, Gauthereau X, Rousseau B, Fevre M, et al: All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene. 35:5619–5628. 2016.PubMed/NCBI View Article : Google Scholar

35 

Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, et al: A biobank of breast cancer explantswith preserved intra-tumor heterogeneity to screen anticancer compounds. Cell. 167(260-274.e22)2016.PubMed/NCBI View Article : Google Scholar

36 

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, et al: Capecetabine efficacy is correlated with TYMP and RB1 expression in PDX established from triple negative breast cancers. Clin Cancer Res. 24:2605–2615. 2018.PubMed/NCBI View Article : Google Scholar

37 

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, et al: A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 172(373-386.e10)2018.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

January-February 2019
Volume 1 Issue 1

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Telang N: Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review). World Acad Sci J 1: 20-24, 2019
APA
Telang, N. (2019). Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review). World Academy of Sciences Journal, 1, 20-24. https://doi.org/10.3892/wasj.2018.3
MLA
Telang, N."Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review)". World Academy of Sciences Journal 1.1 (2019): 20-24.
Chicago
Telang, N."Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer (Review)". World Academy of Sciences Journal 1, no. 1 (2019): 20-24. https://doi.org/10.3892/wasj.2018.3